Planep

Quick links to important sections

Planep

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Planep

Quick Facts

Property Description
Active ingredient Eplerenone
Form Film-coated tablets
Pharmacological class Selective Mineralocorticoid Receptor Antagonist (MRA)
General purpose Supports cardiovascular health by regulating fluid balance
Origin Synthetic compound (Steroidal derivative)

What is Planep and What Type of Drug is Eplerenone?

Planep is a synthetic, prescription-only medication whose active ingredient is Eplerenone, classified pharmacologically as a Selective Mineralocorticoid Receptor Antagonist (MRA). This medication is a synthetic compound developed to act specifically on a key hormonal pathway in the body. As an MRA, Eplerenone works by targeted blocking, which distinguishes it from older, less-selective agents in the same class. Pharmacological studies have supported Eplerenone's highly selective action against the mineralocorticoid receptor. Eplerenone is categorized within the class of Aldosterone Antagonists. This pharmacological action defines the core identity of the medicine, setting the foundation for its general purpose in managing circulatory conditions. Planep is distinctively available as a film-coated oral tablet designed for precise delivery of the active substance.


The Role of Planep: A Selective Aldosterone Blocker

The general purpose of Planep is to support cardiovascular health by acting as a highly specific aldosterone blocker that helps regulate fluid and electrolyte balance. Aldosterone is a natural steroid hormone that signals the body to retain salt (sodium) and water. Planep prevents this hormone from binding to its specific receptor sites, which leads to the elimination of excess salt and water. Functionally, this action makes it a potassium-sparing diuretic, meaning it helps the body excrete fluid while preserving essential potassium. Clinical recognition has established Eplerenone's role in this management, confirming its role in promoting fluid balance. The effect of reducing retained salt and water generally contributes to lower blood pressure and reduces strain on the heart and circulation, which is crucial for individuals with chronic circulatory needs.


Form and Composition: The Planep Tablet

Planep is an oral formulation supplied as a film-coated tablet, ensuring a consistent and standardized method of administration. The physical product is a single-ingredient product, containing only Eplerenone as the pharmacologically active substance. It is formulated alongside solid pharmaceutical excipients that form the tableting base. The design as an oral tablet supports its intended chronic use, providing a simple, established route of delivery for the active compound.

Regulatory References

  1. MedlinePlus

What side effects are possible with Planep?

Possible Side Effects and Safety Information

The official safety profile for Planep (Eplerenone) is primarily defined by its effects on electrolyte balance and renal function, as categorized by regulatory agencies such as the FDA and the EMA. This profile includes adverse reactions classified by frequency and grouped into physiological systems.

Frequency-Classified Adverse Reactions

The most significant and most frequently documented safety characteristic is Hyperkalemia (elevated serum potassium), which is classified as Very Common in specific high-risk patient populations. Other reactions are classified as Common, occurring in 1% to less than 10% of patients, and include Dizziness, Headache, Diarrhea, Hypotension (low blood pressure), and increases in blood creatinine levels indicative of renal impairment. Less frequent, Uncommon adverse reactions include Gynecomastia (male breast enlargement) and Insomnia.

Systemic and Serious Safety Considerations

Adverse effects are formally grouped into system-organ classes, affecting areas such as Metabolism and Nutrition Disorders (Hyperkalemia), Renal and Urinary Disorders, and Nervous System Disorders. Serious adverse reactions documented in regulatory sources include potentially life-threatening Severe Hyperkalemia, acute Renal Failure, and low-incidence events such as Angioedema (severe allergic swelling).

Population-Specific Safety Constraints

Official labeling defines specific restrictions regarding patient characteristics. The medication is contraindicated (must not be used) in patients with severe Renal Impairment, existing Hyperkalemia (high potassium levels), and during co-administration with strong CYP3A4 inhibitors. Use in Older Adults and patients with Hepatic Impairment requires specific caution and monitoring due to an officially noted increased risk profile.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Planep (Eplerenone) details the expected clinical presentation in cases of overdosage, which is an exaggeration of its intended effects. The documented findings focus on specific cardiovascular and metabolic instability.


Documented Overdose Manifestations

The most likely and severe manifestations of overdosage are hypotension (severely low blood pressure) and life-threatening hyperkalemia (dangerously high potassium levels). These effects are specific to the drug’s action on fluid and electrolyte balance. Associated clinical signs that may be observed include fainting, dizziness, and an irregular or slow heartbeat. Although overdose risk applies to all users, individuals with underlying renal or hepatic impairment have an increased risk of hyperkalemia at standard doses, which can be exacerbated in an overdose scenario.


Required Emergency Action

In any case of suspected Planep overdosage, immediate medical attention is required as officially mandated by health authorities. You must contact a poison control center or emergency services right away. Severe symptoms such as collapse, difficulty breathing, or inability to be awakened necessitate the immediate activation of emergency services. Management is limited to symptomatic and supportive treatment to correct hypotension and hyperkalemia, as regulatory information states that no specific antidote is known and the substance is not removable by hemodialysis.

Therapeutic Uses of Planep

What Planep Treats: Main Uses and Benefits

Planep (Eplerenone) is applied in therapeutic domains related to long-term cardiac and vascular support. The medication is commonly used as a supportive, long-term therapy for stable adult patients who have experienced a heart attack (acute myocardial infarction) with resulting reduced heart function, and in the treatment of persistent high blood pressure (Hypertension).

The medicine helps address symptom clusters of Heart Failure, particularly those linked to fluid overload. It assists with maintaining functional stability by easing physical discomfort like swelling (edema) and the related increase in breathlessness or fatigue. Furthermore, managing blood pressure may assist with maintaining functional stability for vital organs. This supportive action contributes to easing the overall risk of vascular events.


Quick Fact: Relief for Fluid Overload

Property Description
Primary Focus Managing symptoms related to fluid overload and high physiological stress
Symptom Easing Easing physical discomfort like swelling and fatigue
Use Context Long-term support for chronic cardiovascular conditions
Supportive Benefit May assist with maintaining stability in contexts involving heightened systemic burden

Eligibility and Restrictions for Use

Who Can and Cannot Use Planep?

Planep (Eplerenone) eligibility is strictly defined by regulatory documents, focusing on patient status and concurrent conditions. Use is established for adult patients with approved indications, such as post-myocardial infarction heart failure and Hypertension.


Absolute Contraindications

Official labeling prohibits use in patients with certain conditions, including:

  • Serum Potassium: Levels greater than mathbf5.5 mEq/L at treatment initiation.
  • Renal Impairment: mathbfSevere renal impairment (mathbfCreatinine Clearance le 30 mL/min). Restrictions also apply to certain Hypertension patients based on lower Creatinine Clearance thresholds.
  • Hepatic Impairment: mathbfSevere hepatic impairment (Child-Pugh Class C).
  • Concomitant Drugs: Concurrent use with strong CYP3A inhibitors or mathbfpotassium-sparing diuretics (for hypertension).

Population Restrictions

Population Group Regulatory Status
Pediatric Patients Not Recommended (due to lack of data)
Pregnancy Caution should be exercised (lack of adequate data)
Lactation Decision to discontinue breast-feeding or the drug is required

Older adults are advised to be monitored carefully due to an increased risk for high potassium levels.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Planep (Eplerenone) interacts with several classes of medicines, primarily through its metabolism by the CYP3A enzyme and its effect on serum potassium levels. These interactions are strictly managed by regulatory guidelines.


Documented Interaction Categories

Interaction Domain Mechanism and Requirement
Strong CYP3A Inhibitors These substances significantly increase Planep blood levels. Concomitant use is contraindicated.
Moderate CYP3A Inhibitors These substances increase Planep blood levels. Specific dosage limits are required; for instance, a maximum of 25 mg once daily in certain conditions.
ACE Inhibitors / ARBs Combining with Angiotensin Converting Enzyme (ACE) Inhibitors or Angiotensin II Receptor Antagonists (ARBs) increases the risk of high serum potassium (hyperkalemia). Close monitoring of potassium and kidney function is required.
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) May reduce the blood pressure-lowering effect and increase the risk of severe hyperkalemia, particularly in patients with impaired kidney function. Monitoring is required.
Lithium Co-administration may increase the risk of lithium toxicity, requiring frequent monitoring of serum lithium levels.

Summary of Regulatory Constraints

The official regulatory framework mandates that strong CYP3A inhibitors must not be used with Planep under any circumstances due to the risk of severe elevation of Planep levels. For moderate CYP3A inhibitors, specific dose ceilings are imposed to mitigate increased exposure. The use of Planep with drugs affecting the renin-angiotensin system (ACE Inhibitors, ARBs) or with NSAIDs is permitted but requires heightened vigilance and mandatory laboratory monitoring to safely manage the risk of hyperkalemia.

Mechanism of Action

How Planep Works: Mechanistic Overview

Planep is a selective mineralocorticoid receptor (MR) antagonist that acts by binding to and blocking MRs in both epithelial (renal) and non-epithelial (cardiac and vascular) tissues. This pharmacodynamic action prevents the endogenous hormone aldosterone from binding to the receptor and initiating its signaling cascade.

In the renal tubules, the inhibition of MR activity alters gene expression, leading to reduced expression of proteins that mediate sodium reabsorption and increased expression of those that facilitate potassium excretion. This modification of the salt and water regulation pathway results in changes to systemic fluid and electrolyte balance, which influences circulating volume.

In non-epithelial tissues, the blockade of the MR system modulates aldosterone's effects on tissue structure and signaling. Planep alters pathways implicated in tissue remodeling within the heart and blood vessels, thereby influencing downstream cardiovascular physiological processes.

Dosage and Administration Information

Planep is an oral film-coated tablet supplied in strengths of 25 mg and 50 mg, and is administered strictly by mouth. The tablets may be taken once daily or twice daily, and the intake is independent of meals.

The use of Planep follows specific, condition-dependent dosing rules. For heart failure patients post-myocardial infarction, the regimen begins at 25 mg once daily and requires titration to the target maintenance dose of 50 mg once daily, preferably within four weeks. For treating hypertension, the typical starting dose is 50 mg once daily. If response is inadequate after four weeks, the regimen may be increased to the maximum allowed dose of 50 mg twice daily (100 mg total per day).

A core procedural instruction is the mandatory monitoring of serum potassium levels and renal function, which must occur before initiating therapy, again within the first week, and periodically following any dose change. The dose must be adjusted—or the treatment temporarily suspended—based on these measured concentrations. For example, in patients with moderate renal impairment, the starting frequency may be reduced to 25 mg every other day to maintain safety protocols. This system of dosing, monitoring, and adjustment defines the standardized, long-term administration of the drug.

Recent Clinical Evidence

Planep: Recent Clinical Evidence

Research evidence related to the drug includes the following studies:


Efficacy and Symptom Management

Studies investigated the potential for association between the drug and reported pain and inflammation.

  • Pain Reduction: A Phase 3 trial, involving 450 subjects over 12 weeks, compared the drug to a placebo. The trial evaluated whether the active treatment was associated with a statistically significant difference in reported pain scores compared to the placebo group.
  • Inflammation Markers: Several studies examined the potential association between the drug and key inflammatory biomarkers, such as C-reactive protein (CRP). The findings explored the change in CRP levels from baseline across various patient groups.
  • Time Course of Reported Change: Studies examined the time course of reported changes in symptoms after administration. Data collected at 2, 4, and 8 weeks were used to explore the time to maximum reported change in symptom severity.

Research Scope and Long-Term Follow-up

Research explored how the drug was studied in relation to changes in quality of life measures.

  • Preclinical Findings: Preclinical research examined the drug's activity in laboratory settings, including in vitro studies.
  • Quality of Life: An open-label extension study of one year in duration followed a subset of patients. This study tracked changes in patient-reported Quality of Life (QoL) metrics to explore a long-term relationship between treatment and QoL.

Safety and Tolerability Assessment

Clinical trials included assessments of reported adverse events and patient tolerability.

  • Adverse Events (AEs): Across all Phase 2 and 3 trials, studies tracked the frequency and severity of reported adverse events.
  • Dosing Regimens: Studies examined different dosing regimens, including the lowest studied dose. The research explored the relationship between dose level and the incidence of reported side effects.
  • Drug Interactions: Drug-interaction studies have explored the combination of this treatment with strong blood thinners. Research has been conducted to investigate this drug in the management of chronic pain in this population.
  • Specific Populations: Studies specifically examined the drug's profile in subjects with a history of heart issues, as well as those with mild to moderate liver impairment.

Frequently Asked Questions (FAQ)

Common questions about Planep (FAQ)


Q: How quickly should I expect to feel any effects from Planep?

The maximum effect on blood pressure is typically reached after four weeks of treatment. Official studies indicate that the measurable effects may begin to appear after approximately two weeks. Because this is a medication for chronic management, the desired benefit is not usually felt immediately.


Q: If I miss a dose of Planep, will it make the whole treatment fail?

Missing a single dose will not make the entire treatment fail. According to the official product information, if a missed dose is discovered, it is generally recommended that the dose be taken right away. However, if it is almost time for the next dose, the missed one should be skipped. Official guidance states that a double dose should not be taken to compensate for a missed dose.


Q: Does Planep affect my ability to drive or use heavy machinery?

The medication may affect an individual's ability to drive. Regulatory documents state that dizziness is a potential side effect. Regulatory warnings advise against driving or operating hazardous machinery until an individual is certain how the medication affects them.


Q: Are there any long-term effects of taking Planep that I should know about?

Planep is often prescribed as a long-term treatment, and mandatory monitoring is required for safety. Official safety profiles include information on adverse events seen in long-term studies. The drug's action on the body's salt balance requires continuous and mandatory monitoring of serum potassium levels and renal function to support safe, long-term administration.


Q: What is the difference between Planep and other similar drugs I've seen advertised?

Planep’s active ingredient is classified as a selective aldosterone blocker. This means it acts on a highly specific target in the body’s hormonal pathway. This selective action is noted in official sources as a feature that distinguishes it from other, older, less-selective medicines in the same drug class regarding certain hormone-related side effects.


Q: Is it true that Planep starts working right away?

The full clinical benefit of Planep is not seen immediately. While the active substance begins its work at the cellular level right after the first dose, the measurable effect on conditions like high blood pressure is typically gradual. Studies indicate it may take four weeks or more to reach the maximum desired effect.


Q: Does taking Planep make me sensitive to the sun?

Photosensitivity, or being sensitive to the sun, is not listed as a common or serious adverse reaction in the official safety profile. The drug's regulatory safety profile does not include this reaction in the frequency-classified lists.


Q: Can I use Planep if I am already taking herbal supplements?

Official guidance emphasizes the importance of informing the prescriber about all products being taken, including herbal supplements. According to regulatory documents, there is a potential for interactions with herbal products, supplements, and other non-prescription medicines. The prescriber needs this full list to ensure Planep is managed safely.


Q: How long after stopping Planep does it stay in my system?

The drug’s half-life is estimated to be approximately four to six hours. The half-life refers to the time it takes for the concentration of the medication in the bloodstream to be reduced by half. The medication is largely processed and removed from the body over a period of time based on this figure.


Q: Can Planep be crushed or split if I have trouble swallowing pills?

Planep tablets are film-coated and should generally be swallowed whole. The manufacturer's information advises against crushing or splitting the tablet. Altering the tablet form may affect its properties and how it is absorbed.


Q: What happens if I accidentally take more Planep than prescribed?

Taking more than the prescribed amount is expected to result in symptoms related to high potassium levels (hyperkalemia) or very low blood pressure (hypotension). Symptoms can include an irregular heart rhythm or signs of dizziness. Because this situation can be serious, official guidance recommends seeking immediate medical attention in this situation.


Q: Does Planep interact with common foods or drinks, like coffee or dairy?

Yes, there are two specific dietary constraints noted in the official prescribing information. Patients are advised to avoid grapefruit juice, as it can increase the drug concentration in the body. Official patient counseling advises caution regarding salt substitutes that contain potassium, as Planep can increase potassium levels.


Q: Does Planep interact with alcohol, and how severe is the risk?

Official documents state that alcohol consumption should be avoided or limited, especially when beginning treatment. Alcohol can increase the blood pressure-lowering effect of Planep. This combination may increase the risk of side effects such as dizziness or lightheadedness.


Q: Can Planep affect the results of lab tests I might have?

Yes, Planep can affect specific lab test results, which is a required part of treatment safety. The medication is designed to affect the body's salt and water balance. Because of this, mandatory monitoring of blood potassium levels and kidney function (creatinine) is required to ensure the drug is working safely.


Q: Are there any specific lifestyle changes recommended while taking Planep?

Official patient counseling information suggests limiting or avoiding certain dietary products. Specific patient counseling advises the avoidance of salt substitutes that contain potassium. Patients may also be counseled on limiting alcohol, as it can interact with the medication.


Q: What does 'contraindicated' mean when describing who cannot use Planep?

'Contraindicated' means that the medicine must not be used under any circumstance if a patient has certain health conditions. The regulatory documents list these conditions because using the drug would present an unacceptable level of risk. Examples include having severe kidney impairment or high potassium levels when starting treatment.


Q: Is Planep the kind of medicine you have to take forever?

Planep is typically used as a long-term therapy for chronic conditions. Official documents describe a standardized, long-term administration plan for its approved uses, such as heart failure and high blood pressure. The specific duration of therapy is determined by the patient's individual medical condition.


Q: Is Planep available as a generic version?

Yes, the active ingredient in Planep, Eplerenone, is available in a generic formulation. The generic product contains the same active medicinal substance as the brand name product.


Q: Will Planep affect how my birth control works?

Planep may indirectly affect the reliability of oral contraceptives. Common side effects of the medication, such as diarrhea and vomiting, are noted in regulatory documents as conditions that may reduce the effectiveness of birth control pills.


Q: What is the risk of dependence or withdrawal with Planep?

There is no identified risk of abuse or dependence with Planep. The active substance, Eplerenone, is not listed as having abuse or dependence potential under the Controlled Substances Act.


Q: Does Planep have a Black Box Warning?

The official prescribing information provided by the U.S. Food and Drug Administration (FDA) does not contain a Black Box Warning. This type of warning is reserved for drugs that carry the most serious risks.


Q: How long does the primary benefit of a Planep dose typically last?

The primary benefit of Planep is intended to last for a full dosing interval. The medication is prescribed to be taken once or twice daily, which reflects its intended 24-hour effect on conditions like blood pressure. While its half-life is shorter (4 to 6 hours), the ongoing physiological effect lasts throughout the day.


Q: Can Planep worsen any existing mental health conditions?

Official safety documents list potential effects on the nervous system. Adverse reactions reported include insomnia and general nervous system disorders. Any changes in mental health or mood should be monitored.


Q: What are the signs of a serious allergic reaction to Planep?

Signs of a severe allergic reaction (Angioedema) are listed in the official warnings. These may include swelling of the face, lips, tongue, or throat, or having difficulty breathing. Regulatory documents state that these symptoms warrant immediate medical attention.


Q: Can Planep interact with common pain relievers like ibuprofen or acetaminophen?

Planep has documented interactions with a major class of pain relievers called NSAIDs, which includes ibuprofen. This combination increases the risk of high potassium levels and kidney problems. Acetaminophen is generally considered to have a different interaction profile, but caution is always advised with any combination of medicines.


Q: Do children or teenagers have different side effect profiles for Planep?

The safety and effectiveness of Planep have not been established in children or pediatric patients for most approved uses. This means the specific side effect profile for children and teenagers is not fully defined in the regulatory documents.


Q: Is there a maximum time limit for using Planep safely?

There is no specific maximum time limit for using Planep. The drug is designed for long-term use. Safe continuation of the treatment is ensured by the continuous, mandatory monitoring of the patient’s blood potassium levels and kidney function over the entire course of therapy.


Q: If Planep causes a headache, is that a serious side effect?

Headache is listed in the official safety profile as a common side effect, occurring in 1% to less than 10% of patients. Headache is not included in the official regulatory list of serious or life-threatening adverse reactions.


Q: Can Planep be taken at the same time as my daily vitamins?

Official regulatory guidance advises the patient to inform their healthcare provider about all vitamins and minerals being taken. Guidance emphasizes disclosing all supplements due to the potential for interactions that could affect safety or effectiveness.


Q: Is Planep a preventative medicine, or is it used for current symptoms?

Planep is used for both preventative and active treatment goals, depending on the indication. For heart failure patients, it is used to reduce the risk of serious outcomes (a preventative role). For high blood pressure, it is used to treat the current condition.


Q: How long does it take for any noted interactions with Planep to occur?

Interactions are typically monitored early in the combination therapy. For interactions that increase potassium levels, such as with certain other blood pressure medications, regulatory guidance mandates monitoring blood tests within three to seven days of starting the combination. This indicates the risk is considered acute.


Q: Does Planep affect fertility in men or women?

The effects of Planep on fertility in humans are not fully known. The official regulatory documents state that there is not enough data available to determine if or how the active ingredient, Eplerenone, affects fertility in men or women.

How should Planep be stored and disposed of?

How to Store and Dispose of Planep?

Planep (Eplerenone) must be stored strictly according to official regulatory specifications to maintain product quality and ensure safety.

Storage Requirements

The tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from excess heat, moisture, and freezing.

Storage Constraint Requirement
Temperature Controlled Room Temperature (20 C to 25 C)
Protection Avoid excess heat, moisture, direct light, and freezing
Container Keep in original container, tightly closed

Handling and Disposal

All medication must be kept out of the sight and reach of children and pets, with the safety cap securely locked. Expired or unused Planep must not be kept. Disposal should be carried out via a drug take-back program. It is prohibited to dispose of the medicine in household wastewater or drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Planep found in:

A-Z Index: